Henrik S G Bodén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henrik S G Bodén has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Olof Sköldenberg
Department of Clinical Sciences at Danderyd Hospital, Division of Orthopaedics, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Agata Rysinska
Department of Clinical Sciences, Division of Orthopaedics, Karolinska Institutet at Danderyd Hospital, S-182 88, Danderyd, Sweden
1 shared publication Hans-Jerker Lundberg
Department of Nuclear Medicine, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden
1 shared publicationMats O F Salemyr
Division of Orthopaedics, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden
1 shared publication- Mats Salemyr
Department of Clinical Sciences, Division of Orthopaedics, Karolinska Institutet at Danderyd Hospital, S-182 88, Danderyd, Sweden
1 shared publication - Olav Muren
Department of Clinical Sciences, Division of Orthopaedics, Karolinska Institutet at Danderyd Hospital, S-182 88, Danderyd, Sweden
1 shared publication
Latest Publications
- Open Access
- 23 April 2016
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 17 (1) , 1-10
Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial
Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA). The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an important regulator of osteoclast activity and bone resorption and is associated with osteolysis around implant. Inhibiting RANKL with denosumab is effective in vivo in preventing osteoporosis-related fractures. In vitro, osteoclasts can be blocked in animal models of osteolysis. We hypothesize that denosumab is effective in reducing wear-induced osteolysis around uncemented acetabular implants in THA. A randomized, double-blind, placebo-controlled trial will be conducted. We will include 110 patients, 40–85 years of age, with a known osteolytic lesion around an uncemented acetabular component ≥7 years after the primary operation. The patients will be randomized in a 1:1 ratio to subcutaneous injections of 60 mg denosumab or placebo for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months. The primary endpoint will be the change in volume of the osteolytic lesion at 3 years measured with three-dimensional computed tomography (3D-CT). Secondary endpoints include functional outcome scores, change in bone mineral density of the lumbar spine, serological markers of bone turnover and adverse events. In vitro results of both bisphosphonates and RANKL inhibitors have been promising, showing reduced osteolysis with treatment. This is, to our knowledge, the first clinical trial testing the efficacy of denosumab in reducing wear-induced osteolysis. The study is an academic, phase II trial from an independent center and is designed to demonstrate efficacy in reducing volume of osteolytic lesions around a total hip arthroplasty. ClinicalTrials.gov ( NCT02299817 ) 2014-11-20
- 23 April 2016
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 17 (1) , 1-10
Open AccessDenosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial
Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA). The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an important regulator of osteoclast activity and bone resorption and is associated with osteolysis around implant. Inhibiting RANKL with denosumab is effective in vivo in preventing osteoporosis-related fractures. In vitro, osteoclasts can be blocked in animal models of osteolysis. We hypothesize that denosumab is effective in reducing wear-induced osteolysis around uncemented acetabular implants in THA. A randomized, double-blind, placebo-controlled trial will be conducted. We will include 110 patients, 40–85 years of age, with a known osteolytic lesion around an uncemented acetabular component ≥7 years after the primary operation. The patients will be randomized in a 1:1 ratio to subcutaneous injections of 60 mg denosumab or placebo for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months. The primary endpoint will be the change in volume of the osteolytic lesion at 3 years measured with three-dimensional computed tomography (3D-CT). Secondary endpoints include functional outcome scores, change in bone mineral density of the lumbar spine, serological markers of bone turnover and adverse events. In vitro results of both bisphosphonates and RANKL inhibitors have been promising, showing reduced osteolysis with treatment. This is, to our knowledge, the first clinical trial testing the efficacy of denosumab in reducing wear-induced osteolysis. The study is an academic, phase II trial from an independent center and is designed to demonstrate efficacy in reducing volume of osteolytic lesions around a total hip arthroplasty. ClinicalTrials.gov ( NCT02299817 ) 2014-11-20
- Open Access
- 1 January 2006
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 77 (6) , 877-885
Continuous bone loss around a tapered uncemented femoral stem: A long-term evaluation with DEXA
Background Periprosthetic bone loss is a well-docu-mented phenomenon after uncemented total hip arthroplasty (THA); however, little is known about how bone mineral density (BMD) changes after 2 years. Patients and methods 14 patients with hip arthrosis (group A) were operated with a proximally porous- and hydroxyapatite-coated stem and followed for 10 years with DEXA, radiographs and Harris hip score (HHS). Another group of 14 patients (group B) was evaluated at 6 and 14 years using the same prosthesis and protocol. Results No stem was revised and all stems were well-Fixed. At final follow-up, HHS was 97 points in group A after 10 years and 94 points in group B after 14 years. Bone mineral changes in group A were greatest in Gruen zones 1 and 7, where the losses were 31% and 26%, respectively, after 2 years on the operated side. The decrease in BMD continued after 2 years and in Gruen zone 7 it was faster than the rate of bone loss on the control side. In group B, the annual change in BMD on the operated side was not significantly different from the bone loss in group A. Interpretation Up to 14 years after implantation of a tapered uncemented stem, the BMD in the calcar region continues to decrease faster than would be expected from normal ageing.
- 1 January 2006
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 77 (6) , 877-885
Open AccessContinuous bone loss around a tapered uncemented femoral stem: A long-term evaluation with DEXA
Background Periprosthetic bone loss is a well-docu-mented phenomenon after uncemented total hip arthroplasty (THA); however, little is known about how bone mineral density (BMD) changes after 2 years. Patients and methods 14 patients with hip arthrosis (group A) were operated with a proximally porous- and hydroxyapatite-coated stem and followed for 10 years with DEXA, radiographs and Harris hip score (HHS). Another group of 14 patients (group B) was evaluated at 6 and 14 years using the same prosthesis and protocol. Results No stem was revised and all stems were well-Fixed. At final follow-up, HHS was 97 points in group A after 10 years and 94 points in group B after 14 years. Bone mineral changes in group A were greatest in Gruen zones 1 and 7, where the losses were 31% and 26%, respectively, after 2 years on the operated side. The decrease in BMD continued after 2 years and in Gruen zone 7 it was faster than the rate of bone loss on the control side. In group B, the annual change in BMD on the operated side was not significantly different from the bone loss in group A. Interpretation Up to 14 years after implantation of a tapered uncemented stem, the BMD in the calcar region continues to decrease faster than would be expected from normal ageing.